eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has been selected for a fourth consecutive year of membership in the dow jones sustainability asia pacific index (djsi asia pacific), the asia pacific version of the dow jones sustainability indices (djsi), which are a family of premier global indices for socially responsible investment (sri).
the djsi family was jointly established between robecosam ag (switzerland) and s&p dow jones indices llc (united states) in 1999 as the first global sri indices in the world and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. this year, the djsi asia pacific has selected 146 companies leading the way in sustainability (68 of which are from japan) from among the region’s top 615 companies. eisai received high scores particularly in categories such as corporate governance, product quality and recall management, human capital development, occupational health and safety as well as strategy to improve access to drugs or products.
in addition to the djsi asia pacific, eisai has been selected for the 15th consecutive year since 2002 as a member of the ftse4good index series, another global benchmark sri index.
the eisai group’s corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. guided by this philosophy, eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.